A clinical study of Safflower Yellow injection in treating coronary heart disease angina pectoris with Xin-blood stagnation syndrome

Zhang Qiong; Peng Jian-hua; Zhang Xiang-nong

doi:10.1007/BF02836509

Your Location：

Home >

Browse articles >

A clinical study of Safflower Yellow injection in treating coronary heart disease angina pectoris with Xin-blood stagnation syndrome

OriginalPaper | Updated：2021-08-27

- A clinical study of Safflower Yellow injection in treating coronary heart disease angina pectoris with Xin-blood stagnation syndrome
- A clinical study of Safflower Yellow injection in treating coronary heart disease angina pectoris with Xin-blood stagnation syndrome
- 中国结合医学杂志（英文版） 2005年11卷第3期页码：222-225
- Affiliations：
  
  1. The National Clinical Base of Drug Research, Xiyuan Hospital, China Academy of Traditional Chinese Medicine,Beijing
  2. Deyuantang Pharmaceutical Ltd. Co., Shangxi
  3. People’s Hospital of Qingdao,China
- Author bio：
- Funds：
  
  Supported by the National High Technology Research and Development Program of China (863 Program), No. 2004AA2Z3692
- DOI：10.1007/BF02836509
  中图分类号：
- 纸质出版日期：2005，
Scan for full text
Qiong, Z., Jian-hua, P. & Xiang-nong, Z. A clinical study of Safflower Yellow injection in treating coronary heart disease angina pectoris with Xin-blood stagnation syndrome., Chin. J. Integr. Med. 11, 222–225 (2005). https://doi.org/10.1007/BF02836509

Zhang Qiong, Peng Jian-hua, Zhang Xiang-nong. A clinical study of Safflower Yellow injection in treating coronary heart disease angina pectoris with Xin-blood stagnation syndrome[J]. Chinese Journal of Integrative Medicine, 2005,11(3):222-225.
Qiong, Z., Jian-hua, P. & Xiang-nong, Z. A clinical study of Safflower Yellow injection in treating coronary heart disease angina pectoris with Xin-blood stagnation syndrome., Chin. J. Integr. Med. 11, 222–225 (2005). https://doi.org/10.1007/BF02836509 DOI：

Zhang Qiong, Peng Jian-hua, Zhang Xiang-nong. A clinical study of Safflower Yellow injection in treating coronary heart disease angina pectoris with Xin-blood stagnation syndrome[J]. Chinese Journal of Integrative Medicine, 2005,11(3):222-225. DOI： 10.1007/BF02836509.

摘要

Objective: To evaluate the clinical effect and safety of Safflower Yellow injection (SYI) in treating coronary heart disease angina pectoris (CHD-AP) with Xin-blood stagnation syndrome (XBSS).Methods: Adopted was the multi-centered

randomized

positive parallel controlled method

448 patients with CHD-AP-XBSS were enrolled and divided into two groups

336 in the tested group treated with SYI and 112 in the control group treated with Salvia injection by intravenous dripping once a day for 14 days

so as to observe the conditions of angina

electrocardiogram

and therapeutic effect on traditinal Chinese medicine (TCM) symptoms as well as the safety of the treatment.Results: The significantly effective rate and total effective rate in the tested group were 60.06% (194/323) and 91.02% (294/323) respectively; those in improvement of TCM symptoms were 40.18% (129/321) and 75. 23% (243/323) respectively

which were better than those in the control group (P<0.01).Conclusion: SYI Injection is effective and safe in treating CHD-AP-XBSS.

Abstract

randomized

positive parallel controlled method

448 patients with CHD-AP-XBSS were enrolled and divided into two groups

336 in the tested group treated with SYI and 112 in the control group treated with Salvia injection by intravenous dripping once a day for 14 days

so as to observe the conditions of angina

electrocardiogram

which were better than those in the control group (P<0.01).Conclusion: SYI Injection is effective and safe in treating CHD-AP-XBSS.

关键词

Safflower yellow injectioncoronary heart disease angina pectorisXin-Blood stagnation syndrome

Keywords

Safflower yellow injectioncoronary heart disease angina pectorisXin-Blood stagnation syndrome

references

Zheng XY. Guiding principle of clinical research on Chinese new drugs. 1st ed. Beijing: Chinese Publishing of Medical and Pharmaceutical Technique, 2002: 69–73.

Special Group of Clinical Nomenclature Standardization, International Association of Heart Diseases and WHO. Standard for nomenclature and diagnosis of ischemic heart disease. Chin J Cardiol 1981; 9(1): 75–76.

National Administration of Drugs Supervising and Managing. Technologic requirement for research of Chinese new drugs. 2000: 29–30.

Zheng QS, Sun RY, Chen ZY. Safety analysis on the regulation of minimal cases in clinical trial of new drugs. Chin J Clin Pharmacol Ther 2003; 8 (3): 354–355.

Zheng QS, Sun RY, Chen ZY. Discussion on the concise calculation and equivalent standard for sample assessment in new drug clinical trial. Chin New Drug J 2003;12 (5): 368–371.

FULL TEXT LINK

More>

浏览量

364

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Thinking on how to construct the system of Chinese medicine efficacy evaluation for coronary heart disease angina pectoris

Clinical non-inferiority trial on treatment of coronary heart disease angina pectoris of Xin-blood stasis syndrome type with lyophilized Salvia salt of lithospermic acid powder for injection